Illustration of the drug MRTX1719 bound to its target protein, protein arginine methyltransferase 5 (PRMT5). This molecule treats solid tumours that contain the methylthioadenosine phosphorylase (MTAP) mutation.
| px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TPG35143127
Source:
達志影像
Authorization Type:
RF
Release Information:
須由TPG 完整授權
Model Release:
N/A
Property Release:
N/A
Right to Privacy:
No
Same folder images:
mrtx1719cancerprmt5mtapinhibitorsmallmoleculestherapeuticstherapeutictreatmentpharmaceuticalmedicinalchemistrydrugdevelopmentproteinstructureligandhealthcaremedicinemedicalpharmacologydrugpharmacologicaloncologyoncologicalcancermalignancycancerousmalignantsolidtumourproteinargininemethyltransferase5methylthioadenosinephosphorylase3dthreedimensionalnobodyno-onemoleculemolecularmodelmolecularstructureartworkillustrationbiochemistrybiochemicalbiologybiologicalcgidigitally-generated
3d5arginineartworkbiochemicalbiochemistrybiologicalbiologycancercancercancerouscgichemistrydevelopmentdigitally-generateddimensionaldrugdrughealthcareillustrationinhibitorligandmalignancymalignantmedicalmedicinalmedicinemethylthioadenosinemethyltransferasemodelmolecularmolecularmoleculemoleculesmrtx1719mtapno-onenobodyoncologicaloncologypharmaceuticalpharmacologicalpharmacologyphosphorylaseprmt5proteinproteinsmallsolidstructurestructuretherapeutictherapeuticsthreetreatmenttumour
Loading